Prescription Justice Home Page

Prescription Justice
BLOG POSTS

02
Jul
2020
Prescription Justice Board of Directors Releases Statement on Covid-19
#
The Prescription Justice Board of Directors recently approved a statement regarding Covid-19. The Board recognizes that Covid-19 infuses the crisis of high drug prices with greater life-and-death urgency.
Read More
10
Mar
2020
Prescription Justice President Submitted Comments to the Food and Drug Administration Regarding Section 804 Importation of Prescription Drugs
#
Gabriel Levitt, President of Prescription Justice submitted comments to the Food and Drug Administration (FDA) in response to the Notice of Proposed Rulemaking (NPRM) titled "Importation of Prescription Drugs, FDA-2019-N-5711, 84 Fed. Reg. 70796.
Read More
21
Feb
2020
Opportunities for Safe Personal Drug Importation under Section 801; Public Comments from Prescription Justice
#
Prescription Justice founder Gabriel Levitt submitted the comments below in response to the FDA’s request for comments on its draft guidance related to “Importation of Certain FDA-Approved Human Prescription Drugs, Including Biological Products, under Section 801(d)(1)(B) of the Federal Food, Drug, and Cosmetic Act: Draft Guidance for Industry.”
Read More
31
Dec
2019
Prescription Justice President’s Statement Becomes Part of the Congressional Record
#
Prescription Justice is proud to announce that a statement prepared by PJ President Gabriel Levitt for the U.S. House Ways and Means Committee on “Investing In The U.S. Health System By Lowering Drug Prices, Reducing, Out-of-Pocket Costs and Improving the Medicare Benefit” is now part of the official congressional record.
Read More
23
Dec
2019
Prescription Justice President Pens Op Ed for The New York Daily News
#
The New York Daily News recently published the Op-Ed United we stand, at least on drug prices by Prescription Justice President, Gabriel Levitt. Mr. Levitt’s Op-Ed underscores the fact that while there is little consensus among voters from different political parties, there is one stark exception: prescription drug prices.
Read More
Tags
Prescription Pharma SUPPORT Act safe and affordable medication Relpax prescription drugs importation FDA drug pricing access to medicines safe and affordable medicines public health World Health Organization board of directors congress Senator Elizabeth Warren pay-for-delay Medicare drug price negotiation medicare drug price negotiation act Senator Angus King trump Ryan Watts Bipartisan cost-related medication nonadherence Seniors PrescriptionJustice rx senate report card big pharma petition online marketplace North Carolina Congressman Mark Walker American Patients First executive authority Rep. Norman Thurston Utah Wholesale Importation U.S. House Ways and Means Committee drug prices Alex Azar HHS Secretary Senate HELP Committee Sanders AARP Klobuchar Medicare Cummings McCain
Archives

Stay informed about news and advocacy centered on the crisis of high drug prices